GlassScriptPhysician profile
Zaleh Parham
NPI 1134459670
$1,561.02
in general payments reported to CMS, 2019-2025
16 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $197 · 2024: $818 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $602.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $216.57 | 2024 | |
| Abbott Laboratories | $189.38 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $124.91 | 2023-2025 | |
| Lilly USA, LLC | $90.70 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $60.29 | 2024-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $42.57 | 2024-2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $38.48 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $36.78 | 2025 | Zoryve |
| Viatris Specialty LLC | $35.39 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.42 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $24.19 | 2025 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $20.01 | 2023 | Aptima, Thinprep 2000 Processor |
| Bausch Health US, LLC | $19.76 | 2024 | Wellbutrin, Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.42 | 2025 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.88 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaleh Parham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.